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The diagnosis of gastrointestinal neuroendocrine neoplasms represents a significant diag-
nostic challenge since these tumours have a various, often non-specific clinical presentation. 
Currently, more than half of gastroenteropancreatic neuroendocrine neoplasms are detected 
incidentally, usually during surgery, diagnostic imaging studies or endoscopic procedures 
performed for other indications. Sometimes the first symptom of the disease is the presence 
of metastatic lesions in the liver. A neuroendocrine tumour is diagnosed based on the clinical 
presentation, assessment of specific and non-specific biochemical markers, imaging studies 
and histopathological examination. Focal lesions, both primary and metastatic may be small 
and often have an atypical location. Diagnostic imaging of neuroendocrine tumours is of 
fundamental importance for determining the location of the primary lesion, staging of the 
disease, selection of treatment and monitoring of its effects. In addition, diagnostic imaging 
make it possible not only to detect tumours, but also to perform therapeutic procedures based 
on the result. Transabdominal ultrasound is one of the first diagnostic imaging method for 
neuroendocrine neoplasms. New ultrasound techniques such as ultrasound elastography, 
contrast-enhanced ultrasound, endoscopic ultrasound, intraductal and intraoperative ultra-
sound improve the efficacy of ultrasound examination. Endoscopic ultrasound is a funda-
mental diagnostic tool for the detection of neuroendocrine tumours of the pancreas and the 
distal part of the colon. Due to the large variety of neuroendocrine tumours and differences 
in tumour biology, clinical stage and expression of somatostatin receptors, no single imaging 
method is sufficient; therefore, in order to determine the right diagnosis and select the best 
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Introduction
Diagnostic imaging of gastrointestinal neuroendocrine 
neoplasms (NEN) is of fundamental importance for deter-
mining the location of the primary lesion, disease staging, 
selection of treatment and monitoring its effects. Currently, 
more than half of gastrointestinal NEN are detected inci-
dentally, usually during surgery, diagnostic imaging stud-
ies or endoscopic procedures performed for other indica-
tions(1,2). Sometimes metastatic lesions in the liver are the 
first sign of the disease when the primary lesion is not yet 
known(1). Focal lesions, both primary and metastatic may 
be small and often have an atypical location, which makes 
NEN imaging and diagnosis difficult. 
Gastroenteropancreatic neuroendocrine 
neoplasms
Gastroenteropancreatic neuroendocrine neoplasms (GEP-
NEN) account for approximately 70% of neuroendocrine 
neoplasms and approximately 1.5–2% of all gastrointestinal 
and pancreatic neoplasms(1,2). GEP-NEN arise from diffuse 
endocrine system (DES) cells present in the pancreas and 
the gastrointestinal system(1,3). Neuroendocrine tumours of 
the pancreas account for 7% of all GEP-NEN and approxi-
mately 10% of all pancreatic neoplasms(4). In recent years 
an increase in the prevalence of gastric and rectal NEN 
versus intestinal NEN has been observed(1,5–10). The NEN 
detection rate has significantly increased over the last few 
decades(1,3). Currently, it is estimated that NEN incidence 
is 3–5.2/100,000 new cases per year. The general preva-
lence rate for these neoplasms is 35/100,000 cases on aver-
age, i.e. 5.86/100,000 individuals per year(1,3). The preva-
lence of NEN in men is higher than that in women (52%; 
5.35/100,000/year vs 48%; 4.76/100,000/year)(1,3). A higher 
risk of the disease has been noted in African Americans, 
Latinos and Asians and the mean age upon diagnosis is 63 
years(5,6). The majority of NEN are sporadic in nature and 
develop approximately 15 years later than the rarer NEN 
associated with genetic syndromes (25%)(4,7). Pancreatic 
neuroendocrine neoplasms (mainly hormonally inactive 
ones) and gastrinoma occur in 25–75% patients with MEN1 
syndrome(7). In patients with a mutation in the VHL gene, 
neuroendocrine tumours are usually benign, while other 
neoplasms occurring in this syndrome (e.g. clear cell renal 
cell carcinoma) are malignant(7,8). Pancreatic neuroendo-
crine neoplasms in NF1 syndrome and tuberous sclerosis 
complex are rare (1%); the diagnosis is made in late-stage 
disease(9).
In the majority of GEP-NEN cases no risk factor for the 
development of a tumour was identified. It was observed 
that hypergastrinaemia, diabetes and ulcerative colitis may 
be associated with the development of NEN, but no cause-
and-effect relationship was confirmed(4).
A special feature of NEN is the production of hormones 
or biogenic amines which can produce numerous clinical 
symptoms. In the case of disease spread symptoms of carci-
noid syndrome may occur such as diarrhoea, tachycardia, 
hot flushes and reddening of the skin(3). The majority of 
NEN are hormonally inactive with uncharacteristic symp-
toms associated mainly with the local development of 
a tumour (abdominal pain, compression, ileus) or spread 
to the liver(4).
Currently, more than half of GEP-NEN are detected inci-
dentally, usually during surgery of the small intestine and 
appendix and in imaging studies or endoscopic proce-
dures performed for other indications(1,4). Sometimes the 
first symptom of the disease is metastatic lesions in the 
liver(1,4). The proportion of small intestinal NEN in which 
the primary lesion was not found is approximately 70%. 
The 5-year survival rate for these patients is estimated to 
be 50%(10).
A neuroendocrine tumour is diagnosed based on clinical 
presentation, assessment of specific and non-specific NEN 
markers, imaging studies and histopathological examina-
tion(4). As for laboratory testing, assay of chromogranin A 
(CgA), which is a characteristic, but non-specific marker, 
may be helpful. The monitoring of changes in the levels of 
this marker may be very helpful for excluding recurrence 
or spread of the neoplastic process, particularly for NEN 
arising from the small intestine(1). Other markers assessed 
depending on the symptoms presented by the patient and 
the suspected type of NEN include: chromogranin B, pan-
creatic polypeptide, gastrin, 5-hydroxyindoleacetic acid 
(5-HIAA), glucose, insulin, C-peptide, glucagon and vaso-
active intestinal peptide (VIP). If MEN1 is suspected, the 
assessment of pituitary function, evaluation of calcium 
and phosphate balance and genetic testing are necessary. 
A diagnostic novelty is NETest with the assessment of 
expression of selected gene transcripts characteristic for 
NEN. The evaluation of circulating microRNA, which are 
stable in body fluids and characteristic for a given neo-
plasm, is a promising method(1,11).
Many different classifications have been proposed in the 
history of neuroendocrine neoplasms. The most recent one, 
adopted by the World Health Organisation (WHO) in 2017, 
introduced a division according to the histological grade 
of the neoplasm (the G feature) and the proliferation index 
(Ki-67) into four groups: NEN G1, G2 and G3 and NEC 
(neuroendocrine carcinoma(1).
The primary method of GEP-NEN management is sur-
gery, whose scope depends on the location of the tumour, 
the stage of the neoplasm and the patient’s condition. 
In selected cases endoscopic treatment is an alterna-
tive method(1). The gold standard of pharmacotherapy in 
patients with NEN is somatostatin analogue treatment for 
hormonally active and inactive tumours, both during stable 
disease and progression(1). Another NEN treatment method 
is chemotherapy, which is selected depending on the stage 
and grade of the disease. For NEN G3 a less aggressive 
capecitabine and temozolomide (CAPTEM) regimen can 
be used, while for NEC cisplatin and etoposide are used(1). 
Molecularly targeted therapies (everolimus and sunitinib) 
are offered particularly for pancreatic NEN(1). In patients 
with metastatic or inoperable NEN with high somatostatin 
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Transabdominal ultrasound has limited utility for detecting 
a primary lesion in the small intestine. It is rarely possible 
to detect a lesion in the intestinal wall using high-frequency 
probes(12). A case of small intestinal tumour diagnosis with 
abdominal ultrasound despite negative results of other 
imaging studies has been reported in the literature(10). 
Secondary lesions in the mesentery (enlarged, hypoechoic 
lymph nodes, mesenteric fibrosis) may be an indirect indi-
cation of a tumour in the intestinal wall(12).
Hepatic metastases of a primary NEN tumour located in 
the lungs, stomach or colon are usually hypo- or isoechoic 
compared to the hepatic parenchyma. In tumours arising 
from the small intestine and pancreas the echogenicity of 
secondary lesions is various and non-characteristic (hypo-, 
iso-, hyperechoic or sometimes mixed lesions). In insuli-
noma tumours, liver metastases usually have decreased 
echogenicity(13–15). Areas of necrosis are usually found in 
large tumours (>3 cm) with a Ki-67 proliferation index of 
>2% and in individuals who have undergone treatment 
(interferon, embolisation, chemotherapy, radiofrequency 
ablation). No necrotic changes were observed in patients 
treated with cold or hot somatostatin analogues(13–15).
On Doppler ultrasound, primary NEN foci and liver and 
lymph node metastases have a rich network of blood ves-
sels. In tumours with Ki-67 >2% the vascular network may 
be irregular(13–15).
The sensitivity of transabdominal ultrasound in the diagno-
sis of metastatic lesions in the liver is 82–88% and its speci-
ficity is 92–95%. The sensitivity for pancreatic tumours is 
lower: 39%(1).
New ultrasound techniques  
in the diagnosis of NEN
In recent years new ultrasound imaging techniques have 
been developed that improve the efficacy of NEN diagno-
sis(15): ultrasound elastography, CEUS, EUS, intraductal 
ultrasound (IDUS) and intraoperative ultrasound (IOUS).
Endoscopic ultrasound (EUS)
Endoscopic ultrasound is an invasive imaging method 
which involves the insertion of a flexible endoscope with 
a high-frequency ultrasound probe (7.5–12 MHz), which 
is positioned near the pancreas, stomach, duodenum or 
rectum. The minimisation of the distance between the 
probe and the abnormality to be evaluated makes it pos-
sible to thoroughly assess anatomical relationships, depth 
of tumour invasion through the gastrointestinal wall and 
the presence of metastases in local lymph nodes(1).
Endoscopic ultrasound is a fundamental diagnostic tool for 
the detection of NEN in the pancreas and the distal part of 
the colon. Combined with simultaneous fine-needle biopsy, 
it is the most sensitive method of pancreatic NEN diagno-
sis. It is a method of choice for the detection of small lesions 
receptor expression on somatostatin receptor scintigraphy 
(SRS), treatment with radiolabelled somatostatin ana-
logues (DOTA-Tyr3-octreotide and DOTA-Tyr3-octreotate 
labelled with radioisotopes 177Lu, 90Y) is recommended, 
which is called peptide receptor radionuclide therapy 
(PRRT)(1).
Diagnostic imaging of NEN
Diagnostic imaging of neuroendocrine tumours plays 
a fundamental role in diagnosis, staging, selection of 
treatment method, assessment for radioisotope therapy 
and monitoring response to treatment(1,2). Diagnostic 
imaging methods make it possible not only to detect 
tumours, but also to perform therapeutic procedures 
based on the result. Diagnostic imaging of NEN is dif-
ficult since the tumours have a various, often non-spe-
cific clinical presentation or are diagnosed incidentally 
in asymptomatic patients. Focal lesions, both primary 
and metastatic may be small and often have an atypical 
location. It is important to use various diagnostic meth-
ods, both morphological and functional. Morphological 
imaging (transabdominal ultrasound, contrast-enhanced 
ultrasound, [CEUS]; elastography; endoscopic ultra-
sound [EUS]; computed tomography [CT]; magnetic res-
onance imaging [MRI]; endoscopy, including video cap-
sule endoscopy [VCE]) is usually used to detect a tumour 
and assess the stage of the disease. Functional imaging 
techniques (scintigraphy with 99mTc-labelled somatosta-
tin analogues [99mTc-SPECT]; positron emission tomog-
raphy with 68Ga-labelled peptides [68Ga-PET/CT] and 
with other tracers: 18F-FDG, 18F-DOPA and 11C-HTP) are 
useful for tumour detection, prognostic assessment and 
treatment planning(4) (Tab. 1). 
Transabdominal ultrasound in NEN
Transabdominal ultrasound is usually a first-line diagnos-
tic imaging procedure for GEP-NEN. The use of various 
ultrasound techniques: harmonic and Doppler imaging, 
computer processing and compound imaging (CI) makes 
ultrasound a commonly used method for the diagnosis and 
monitoring of NEN. It is also possible to perform ultra-
sound-guided biopsy of tumours located in the liver, pan-
creas and retroperitoneal space. 
The sensitivity of this method depends on the location of 
abnormalities, anatomical conditions, experience of the 
physician performing the procedure and technical aspects 
of the ultrasound device(1). The sonographic image of NEN, 
both the primary lesion and liver metastases is non-charac-
teristic; it depends on the type of NEN, proliferation index, 
tumour size and location and on the presence of regressive 
changes(1).
A pancreatic neuroendocrine neoplasm is often well-
defined, hypoechoic (less commonly hyper- or nor-
moechoic), sometimes with a hyperechoic halo, areas of 
necrosis and calcifications(1,4).
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Method Advantages Disadvantages
Ultrasound
• No exposure to ionising radiation
• Repeatability
• Transabdominal ultrasound – wide availability
•  EUS – primary method for pancreatic tumour assessment 
(EUS + CEUS, elastography)
• EUS-FNA – possibility of cytological verification 
• EUS-RFA – possibility to treat focal lesions of the pancreas
•  CEUS, elastography – improved sensitivity for focal lesion 
assessment, evaluation of unclear lesions on CT/MRI
• IOUS – possibility of intraoperative lesion assessment
• IDUS – thorough assessment of intraductal lesions
•  Assessment dependent on the skills and experience of the 
examiner and the class of the device 
• Poorer sensitivity of the classic method




• High spatial resolution (min. 2–4 mm)
• Thorough anatomical assessment of abdominal organs
• Multiplanar imaging, 3D reconstruction
• Disease staging
•  Assessment of intestinal focal lesions (enteroclysis, 
enterography, CT colonoscopy)
• Aid in surgery planning 
• Availability, quick results, repeatability
• Exposure to ionising radiation
•  Exposure to iodine contrast agent and the associated 
complications (renal failure, allergic reactions, 
hyperthyroidism)
•  Vasculature assessment dependent on the phase and dose 
of contrast
•  Difficult reassessment of both small and too large lesions in 
terms of volume
•  Difficult assessment of response to treatment if necrosis, 
haemorrhage or fibrosis are present with no reduction in 
lesion size




• High spatial resolution (min. 2–4 mm)
• Best differentiation between soft tissues
• Multiplanar imaging, 3D reconstruction
• Disease staging
•  The best method for the assessment of hepatic and 
pancreatic focal lesions
•  Assessment of bile duct and pancreatic duct – MRI 
cholangiopancreatography
• No exposure to ionising radiation





• Long duration of procedure
• Patient cooperation required
• Contraindication: metal parts in the body
•  Difficult reassessment of both small and too large lesions in 
terms of volume
•  Difficult assessment of response to treatment if necrosis, 
haemorrhage or fibrosis are present with no reduction in 
lesion size




• CT imaging possible
• Assessment of primary lesion location, stage of the disease
•  Evaluation for appropriate forms of treatment, assessment of 
treatment response, evaluation for PRRT
• Monitoring, reassessment 
• 1-day procedure, SPECT 4 hours after tracer administration
• Exposure to ionising radiation
• Low resolution, poor assessment of lesions <1 cm
•  High background hinders midgut NEN assessment on 
gastrointestinal examination 
• Low sensitivity in insulinoma detection




•  Multiplanar imaging, high resolution 4–6 mm, imaging 
together with CT
•  Possibility to calculate the level of uptake – standardised 
uptake value (SUV)
• Good anatomical assessment
•  Assessment of primary lesion location, stage of disease, 
evaluation for appropriate forms of treatment, assessment of 
treatment response, monitoring, reassessment 
• Assessment for PRRT
• 1-day procedure, images obtained quickly, after 2 hours
•  Uptake in normal tissues (pituitary gland, spleen, kidneys, 
adrenal glands) or in inflammatory foci may be mistaken for 
a tumour
• Possible interference with cold somatostatin analogues
• Lack of complete validation
Tab. 1.  Comparison of selected diagnostic imaging methods for GEP-NEN(1,12,18,19)
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•  Multiplanar imaging, high resolution 4–6 mm, imaging 
together with CT 
• Good anatomical assessment
•  Disease staging, assessment of treatment response, 
prognostic factor, monitoring 
• For the assessment of poorly differentiated NEN
• Prognostic value in highly and medium differentiated NEN
• Exposure to radiation
• Poor uptake in NEN G1 and G2




•  High specificity for phaeochromocytoma, paraganglioma, 
neuroblastomas
• Assessment for treatment with 131I-MIBG
• High background
• Poor anatomical assessment
• Interference from many pharmaceuticals
•  Need for preparation with organic iodine in order to block 
the thyroid gland before the procedure
• Procedure 24–72 hours after tracer administration
EUS – endoscopy ultrasound; EUS-FNA – EUS fine-needle aspiration; EUS-RFA – EUS-guided radiofrequency ablation; CEUS – contrast-enhanced 
ultrasonography, IDUS – intraductal ultrasonography; IOUS – intraoperative ultrasonography; SRS – somatostatin receptor scintigraphy; SSA – 
somatostatin analog; PRRT – peptide-receptor radionuclide therapy; 99mTc-SPECT – 99mTc-single-photon emission computed tomography; 68Ga-DOTA-
PET – 68Ga-DOTA-positron emission tomography; 18FDG-PET – 18FDG-positron emission tomography; 131I-MIBG – 131I-MIBG – single-photon emission 
computed tomography
Tab. 2.  Proposed diagnostic methods for GEP-NEN(1,2,18,19)
Suspected NEN of the stomach, duodenum
1. Gastroscopy with histopathological examination (determination of histopathological diagnosis)
2. EUS (assessment of intramural invasion depth the presence of metastasis in regional lymph nodes) – lesions of 1–2 cm or multiple lesions
3.  Abdominal CT scan – after filling the stomach with water to the full (stomach assessment) or 2-stage water drinking (assessment of the duodenum) 
and i.v. contrast administration / contrast-enhanced MRI – disease staging, distant metastasis detection
4. SRS – disease staging, distant metastasis detection
Suspected NEN of the pancreas
1. EUS – in every case with clinical diagnosis of a secreting tumour and when indications for biopsy are present
2.  Hormonally active NEN of the pancreas – SRS (detection of lesions not revealed using anatomical imaging, search for the primary lesion and 
determination of the actual stage of the neoplasm; first-line method for the diagnosis of early recurrence, disease monitoring and selecting the 
right therapy), subsequently EUS and CT/MRI (assessment of anatomical location and the possibility to remove the primary lesion, cancer staging 
and treatment response monitoring)
3. Hormonally inactive NEN of the pancreas: CT/MRI (as above), subsequently SRS (as above) 
4. Rapidly growing NEC and NEN of the pancreas – 18FDG PET/CT
Suspected NEN of the small intestine, metastatic NEN of unknown point of origin
1. SRS – method preferred for lesions smaller than 1 cm, search for the primary lesion 
2. CT, MRI – search for the primary lesion, disease staging and assessment of treatment response
3. CT or MRI enterography/enteroclysis – determination of location
4. Colonoscopy with distal ileum assessment – search for the primary lesion and exclusion of concomitant cancer (colon cancer)
5.  Video capsule endoscopy (VCE) and balloon enteroscopy or spiral enteroscopy – direct assessment of the mucous membrane; poorly available 
procedure
6. EUS – no utility for small intestinal lesion diagnosis 
Suspected NEN of the colon
1. Colonoscopy – procedure of choice in the diagnosis of colon tumours
2. EUS – in rectal NEN of ≥5 mm; ultrasound miniprobes during colonoscopy – in colon tumours diagnosed as polyps/submucosal lesions 
3. Abdominal and pelvic CT/MRI with the gastrointestinal tract filled with negative contrast – disease staging and assessment of metastases
4. CT colonography – it is not possible to perform complete colonoscopy in the case of lesions which fully obstruct the intestinal lumen
5. SRS – staging of the neoplastic process, assessment for SSA and PRRT
6. PET-CT following 18F-DOPA assessment – in the case of a negative SRS result assessment for antiproliferative treatment using SSA and PRRT
7.  18FDG-PET/CT – in patients with NEC, patients with a rapidly growing NET with a negative SRI result and in patients assessed for radioisotope 
treatment 
EUS – endoscopy ultrasound; EUS-FNA – EUS fine-needle aspiration; EUS-RFA – EUS-guided radiofrequency ablation; CEUS – contrast-enhanced ultra-
sonography; IDUS – intraductal ultrasonography; IOUS – intraoperative ultrasonography; SRS – somatostatin receptor scintigraphy; SSA – somatostatin 
analog; PRRT – peptide-receptor radionuclide therapy; 99mTc-SPECT – 99mTc-single-photon emission computed tomography; 68Ga-DOTA-PET – 68Ga-
-DOTA-positron emission tomography; 18FDG-PET – 18FDG-positron emission tomography; 131I-MIBG – 131I-MIBG – single-photon emission computed 
tomography
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(even 1–2 mm), particularly those hormonally active and 
a screening method for patients with genetic abnormali-
ties (e.g. with MEN1 syndrome)(4). In a multi-centre ret-
rospective study investigating the size of pancreatic NEN 
in patients with MEN1 syndrome using EUS more than 
90% of small lesions of less than 7 mm were visualised(16). 
In other studies the sensitivity of EUS depended on the 
location of the focal lesion and was 77–100% for tumours 
located in the head and body of the pancreas and 75–80% 
for tumours located in the distal part of the pancreas(1,17). 
Recent studies report that the sensitivity of EUS may be 
higher than that of computed tomography (91.7% vs 
63.3%), particularly for insulinoma (84.2% vs 31.6%)(1,2,4). 
The sensitivity of EUS in the detection of doudenal lesions 
is 45–60%(1,2). Comparative studies on conventional exami-
nation methods (transabdominal ultrasound, CT and MRI) 
demonstrated their lower sensitivity compared to EUS(16).
Hormonally active pancreatic neuroendocrine tumours 
present as single homogeneous, hypoechoic solid tumours 
(less often normo- and hyperechoic ones) which are char-
acterised by intensive enhancement following contrast 
administration(16). A cystoid form of the tumour may occur 
in approximately 10–20% of patients(18). Calcifications in 
hormonally active and inactive NEN of the pancreas may 
be found in approximately 25% of cases, while being rarely 
observed in adenocarcinomas. In larger tumours, the pan-
creatic duct may become dilated and the pancreatic paren-
chyma may undergo atrophy(1,18). EUS plays an important 
role in disease staging, assessment of blood vessel invasion 
and differential diagnosis of pancreatic tumours of unclear 
nature (distinguishing between NEN and adenocarcino-
mas, cystoid lesions and tumours with atypical, poor vascu-
lature). It may be stated that EUS combined with Doppler 
ultrasound, contrast, elastography and EUS-guided biopsy 
makes it possible to detect all pancreatic NEN(1,18).
In diagnostic imaging of rectal tumours endoscopic ultra-
sound is also the most sensitive method for preoperative 
local staging. A neuroendocrine neoplasm in the form of 
a polyp presents as a well-defined, iso- or hypoechoic, 
homogeneous lesion on EUS(19). The sensitivity of this 
method in the assessment of the tumour and the depth of 
its invasion in the rectal wall is 76–93%. For the assessment 
of metastases in the nearby lymph nodes the sensitivity is 
61–88%(1,2,4,19).
The assessment of lesions located in the distal part of the 
ileum is possible on EUS using high-frequency miniprobes 
inserted through the biopsy channel of a colonoscope(4,19).
An advantage of EUS is also the fact that it is possible to 
insert a radiofrequency ablation (RFA) probe in the echo-
endoscope channel, which causes thermal coagulation 
necrosis of the tumour. It has been demonstrated that this 
technique is safe and effective in patients with hormonally 
active NEN of the pancreas who were denied surgery due 
to comorbidities(13). The disadvantages of EUS include the 
fact that the result depends on the skills and experience of 
the examiner and that the field of vision is limited, which 
may reduce its efficacy in detecting lesions beyond the area 
of interest(4).
I t is possible to achieve an even better visualisation of 
pancreatic NEN in the immediate vicinity of the pan-
creatic duct and abnormalities in its lumen by inserting 
a miniprobe to the pancreatic or bile duct through the 
biopsy channel of an endoscope (IDUS)(1). The sensitivity 
of the procedure is around 94% and approximates 100% 
if the abnormalities in the pancreatic duct are larger than 
3 mm(20).
Contrast-enhanced ultrasound (CEUS)
Third-generation contrast agents used for ultrasound 
diagnosis are gas-filled microvesicles coated with phos-
pholipids with a long half-life and perfusion-dependent 
greyscale image enhancement(1). On CEUS, focal lesions 
are assessed based on characteristic vasculature patterns 
indicating benign or malignant abnormality(15). Primary 
pancreatic NEN, even small ones, have a good network 
of blood vessels. Following contrast administration, pan-
creatic NEN show intensive enhancement in the arterial 
phase(16). The majority of NEN metastases in the liver (78–
86%) show enhancement in the arterial phase following 
contrast administration with a quick contrast clearance in 
the venous phase(1,16,17). Wen-Tao et al. demonstrated that 
metastases with a rich vasculature demonstrated a longer 
contrast clearance time compared to those with a poorer 
vasculature. The assessment of both primary and metastatic 
tumours using CEUS may replace other contrast-enhanced 
imaging techniques in the majority of cases, particularly if 
there are contraindications to those procedures(16). CEUS is 
useful in the detection of small tumours of less than 2 cm, 
with a comparable sensitivity to EUS (95%)(1).
Elastography
Ultrasound imaging using elastography is an increas-
ingly available technique allowing one to assess tumour 
hardness. This method may be used to assess focal lesions 
in the pancreas on EUS and focal lesions of the liver on 
transabdominal ultrasound. In a study by Iglesias-Garcia 
et al., the sensitivity of quantitative EUS elastography in 
differentiating between pancreatic adenocarcinoma and 
NET was 100% and its specificity was 88% for the strain 
ratio (SR) cut-off value of 26.6(21,22). In general, the sensitiv-
ity and specificity of differentiating between benign and 
malignant lesions were 93% and 86%, respectively, while 
the SR limit value was 6.0. In a metanalysis on qualitative 
EUS elastography in the diagnosis of pancreatic tumours 
a high sensitivity (95%) and an acceptable low specificity 
(67%) were observed(21,22). Qualitative and quantitative EUS 
elastography may be a valuable supplementary method 
used to differentiate between benign and malignant pan-
creatic lesions(21). According to the recommendations of 
the European Federation of Societies for Ultrasound in 
Medicine and Biology (EFSUMB), EUS elastography 
may be helpful in making therapeutic decisions in cases 
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Due to their rare occurrence, atypical symptoms and slow 
growth, the majority of NEN are diagnosed with a few 
years’ delay, usually at an advanced stage. Only some neu-
roendocrine tumours present with characteristic signs of 
hormonal activity, suggesting the diagnosis(1,12,18,19).
Sometimes in asymptomatic patients or patients undergo-
ing ultrasound examination for non-specific abdominal 
pain a primary lesion is found in the pancreas, less often 
in the stomach, duodenum or the retroperitoneal space. 
Metastatic foci in the liver or lymph nodes may also be 
found. The search for the primary lesion in a patient with 
metastatic NEN of an unknown point of origin may be 
particularly difficult since primary lesions are often small. 
Depending on the type of visualised changes the examiner 
should propose a further diagnostic algorithm. 
In a reverse situation when NEN is diagnosed based on 
clinical symptoms and/or biochemical testing, the key steps 
are to search for the primary lesions and make a base-
line assessment of the stage of the neoplastic process. 
Depending on the symptoms and the type of the suspected 
NEN one should identify the possible sites of the tumour 
focusing on the pancreas, intestines, appendix, mesentery 
and retroperitoneal space (Tab. 2).
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where fine-needle biopsy performed during EUS has no 
diagnostic value. However, elastography alone cannot 
replace cytological assessment(21,22). Elastography of focal 
hepatic lesions allows one to make a preliminary distinc-
tion between MEN metastases and primary benign focal 
hepatic lesions. However, the results may be doubtful in 
obese patients or in the case of lesions located near the 
ribs(21,22).
Intraoperative ultrasound 
Intraoperative ultrasound (IOUS) is used mainly to diag-
nose focal lesions in the liver and pancreas, particularly 
in patients with multiple endocrine neoplasia (MEN) syn-
dromes. The procedure also makes it possible to detect 
multifocal tumours and metastatic lesions in the liver and 
assess the distance of a pancreatic tumour, particularly 
a small one, from the pancreatic duct(1). The sensitivity of 
IOUS in the detection of tumours is 90%(1).
Conclusion
Transabdominal ultrasound is usually the first diagnostic 
imaging procedure for NEN. However, the possibility of 
precise staging of the disease using transabdominal ultra-
sound is limited due to a number of factors (technical 
aspects of the procedure, small tumour dimensions and 
often unfavourable location inaccessible to transabdomi-
nal ultrasound). New ultrasound techniques improve the 
precision of the diagnosis and constitute an important part 
of a NEN diagnostic process. 
Patients with NEN may show a large discrepancy between 
the clinical presentation and actual stage of the disease. 
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